A5101797289- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Molecular Biology Techniques and Applications
- Neuroblastoma Research and Treatments
- Cardiac, Anesthesia and Surgical Outcomes
- Ovarian cancer diagnosis and treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Colorectal Cancer Treatments and Studies
- Cardiac and Coronary Surgery Techniques
- Urinary and Genital Oncology Studies
- Heat shock proteins research
- Microbial Natural Products and Biosynthesis
- Neuroendocrine Tumor Research Advances
Liaoning Cancer Hospital & Institute
2023
Tianjin Medical University
2020-2021
Tianjin Chest Hospital
2010-2021
Nankai University
2021
Tianjin Nankai Hospital
2020
Tianjin Hospital
2020
Background: Epidemiological and clinical prognosis differences between male female lung adenocarcinoma (LUAD) patients have been frequently reported. To improve determinations, gender-specific nomogram models should be developed validated to predict the of with LUAD. Methods: Using Surveillance, Epidemiology, End Results (SEER) database, LUAD diagnosed 2010 2015 were used as SEER training internal validation testing sets. Patients in Tianjin Chest Hospital postoperative pathological...
Abstract Background The 5‐year survival rate of non‐small cell lung cancer (NSCLC) is only 15%. Screening some combined gene mutations could predict the NSCLC patients and also provide new ideas for diagnosis treatment NSCLC. present study aimed to identify signature prediction Methods Clinical mutation information 949 was downloaded from TCGA. High frequency common genes were analyzed based on 1000 related genes. LASSO‐COX model used screen points analyze their survival, then a established....
This study sought to assess the safety and efficacy of a lobectomy combined with off-pump coronary artery bypass grafting (OPCABG) among patients lung cancer.Patients who underwent simultaneous pulmonary OPCABG at Tianjin Chest Hospital from December 2010 June 2019 during same period were selected ratio 1:2 using multi-factor propensity score for this study. The clinical data each group operation perioperative analyzed compared, survival curves drawn Kaplan-Meier method compare long-term...
Abstract Background and Purpose: Lung cancer is the most frequent malignant tumor in China. Epidermal growth factor receptor (EGFR) had been validated as one of important therapeutic targets non-small cell lung (NSCLC), tyrosine kinase inhibitors (TKI) have improved overall outlook quality life for EGFR mutation positive NSCLC patients; however, fact that 30% patients still do not response to TKIs. The current diagnostic test qualitatively measures status tissue, ignored impacts nonmutated,...
The PACIFIC trial established consolidation therapy with durvalumab as the standard of care for patients (pts) unresectable stage III non-small cell lung cancer (NSCLC) without progression after chemoradiotherapy (CRT), however, additional studies are still needed to further explore optimal therapeutic strategies. Here, we reported preliminary results phase 2 study camrelizumab (an anti-PD-1 antibody) plus apatinib anti-angiogenic inhibitor targeting VEGFR2) CRT in NSCLC. This was a...